Corvus Pharmaceuticals AI Stock Analysis
Want to see CRVS full AI Analyst Report?
Corvus Pharmaceuticals (CRVS) AI Stock Analysis
Corvus Pharmaceuticals
(NASDAQ:CRVS)
The score is held back primarily by weak financial performance (no meaningful revenue, recurring losses, and significant cash burn) and bearish technicals (trading below major moving averages with negative momentum). These are partially offset by a strong balance sheet with very low leverage and a constructive earnings call outlook, including runway into Q2 2028 and multiple expected 2027 clinical catalysts, though the PTCL futility check remains a notable near-term risk.
Corvus Pharmaceuticals (CRVS) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $894.14M
- Dividend Yield
- ―
- Average Volume (3M)
- 1.04M
- Price to Earnings (P/E)
- -13.9
- Beta (1Y)
- 1.00
- Revenue Growth
- ―
- EPS Growth
- -272.40%
- Country
- US
- Employees
- 37
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Corvus Pharmaceuticals Business Overview & Revenue Model
Company Description
Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm specializing in the development and commercialization of immuno-oncology therapies. Their leading investigational compound, Mupadolimab (CPI-006), an anti-CD73 monoclonal antibod...
Corvus Pharmaceuticals Earnings Call Summary
The call was predominantly positive, with enrollment on track or ahead of plan across multiple programs, favorable early ALPS results, a strong cash position extending the operating runway into the second quarter of 2028, and several clinical milestones expected in 2027. The main negatives were increased R&D spending, a wider net loss, higher stock compensation, the modest extension of Angel's data timing, and the possibility that the PTCL trial could be stopped for futility.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Based on cash, cash equivalents and marketable securities of $202.9 million as of September 30, 2026, Corvus expects its cash to fund operations into the second quarter of 2028; the Phase 3 PTCL futility analysis is anticipated in the first quarter of 2027 and top line data before the end of the year 2027, while SEERA-1 was planned to enroll approximately 200 patients across 3 soquelitinib doses and a placebo group with top line data anticipated in the third quarter of 27 and a potential Phase III start in 2028; ANGEL cohort 2 is expected to begin enrolling in November, with cohort 2 data potentially available in the second half of 2027, and an additional 60 to 90 patients anticipated in the Phase 2 portion; the HS Phase 1b trial is designed to enroll up to 25 patients and may report data in the first half of 2027; Corvus is on track to initiate the asthma trial in the first quarter of 2027, and both Corvus and Angel plan to launch asthma trials in 2027.
Corvus Pharmaceuticals Financial Statement Overview
Summary
Financials reflect an early-stage biotech profile: essentially no revenue, recurring operating losses, and worsening TTM net loss alongside deeply negative operating/free cash flow. The main offset is a strong, low-leverage balance sheet (very low debt vs. sizable equity), which supports resilience but does not remove ongoing burn/financing risk.
Income Statement
12Very NegativeBalance Sheet
66PositiveCash Flow
24Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | -26.00K | -105.00K | 0 | 0 | 0 | 0 |
| EBITDA | -61.93M | -15.18M | -62.21M | -26.88M | -40.94M | -42.77M |
| Net Income | -64.31M | -15.28M | -62.29M | -27.03M | -41.31M | -43.24M |
Balance Sheet | ||||||
| Total Assets | 223.88M | 71.12M | 68.91M | 45.55M | 68.24M | 109.45M |
| Cash, Cash Equivalents and Short-Term Investments | 202.95M | 56.75M | 51.96M | 27.15M | 42.30M | 69.45M |
| Total Debt | 632.00K | 937.00K | 1.12M | 1.37M | 2.60M | 3.65M |
| Total Liabilities | 15.56M | 9.91M | 36.34M | 6.87M | 12.13M | 12.29M |
| Stockholders Equity | 208.32M | 61.20M | 32.57M | 38.68M | 56.12M | 97.16M |
Cash Flow | ||||||
| Free Cash Flow | -47.94M | -32.97M | -25.42M | -23.97M | -27.29M | -36.72M |
| Operating Cash Flow | -47.18M | -32.80M | -25.42M | -23.93M | -27.02M | -36.72M |
| Investing Cash Flow | -132.41M | -7.80M | -27.48M | 15.54M | -23.28M | 21.56M |
| Financing Cash Flow | 191.74M | 36.43M | 49.03M | 7.86M | 0 | 62.16M |
Corvus Pharmaceuticals Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CRVS, the sentiment is Negative. The current price of 10.17 is below the 20-day moving average (MA) of 10.48, below the 50-day MA of 11.03, and below the 200-day MA of 13.89, indicating a bearish trend. The MACD of -0.07 indicates Negative momentum. The RSI at 44.54 is Neutral, neither overbought nor oversold. The STOCH value of 38.79 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CRVS.
Corvus Pharmaceuticals Risk Analysis
Corvus Pharmaceuticals disclosed 73 risk factors in its most recent earnings report. Corvus Pharmaceuticals reported the most risks in the "Tech & Innovation" category.
Latest Risks Added
3 New RisksCorvus Pharmaceuticals Peers Comparison
Overall Rating
XNCR61Neutral
CRVS51Neutral
KURA48Neutral
IMTX46Neutral
CTMX44Neutral
ORIC44Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 61Neutral | $2.59B | -22.05 | -21.29% | ― | 33.55% | 11.51% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 51Neutral | $857.87M | -13.86 | -34.98% | ― | ― | -272.40% | |
| 48Neutral | $688.17M | -2.26 | -336.24% | ― | -23.76% | -33.09% | |
| 46Neutral | $941.21M | -3.33 | -52.19% | ― | -44.50% | -80.18% | |
| 44Neutral | $422.93M | -4.28 | -33.97% | ― | -87.66% | -210.45% | |
| 44Neutral | $831.45M | -5.35 | -40.99% | ― | ― | 15.37% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| CRVS | Corvus Pharmaceuticals Inc. | 10.17 | 1.27 | 14.27% | |
| XNCR | Xencor Inc. | 34.50 | 18.73 | 118.77% | |
| CTMX | CytomX Therapeutics Inc. | 1.94 | -1.69 | -46.56% | |
| KURA | Kura Oncology | 7.49 | -3.83 | -33.83% | |
| ORIC | Oric Pharmaceuticals Inc | 8.00 | -3.48 | -30.31% | |
| IMTX | Immatics N.V. | 6.29 | -4.04 | -39.11% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 06, 2026
